ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2020年06月19日 15時00分
Source:
Eisai
エーザイ、人事異動(2020年6月19日付)を発表
東京, 2020年06月19日 - (JCN Newswire) - エーザイは本日、人事異動(2020年6月19日付)を以下のとおり発表しました。
<2020年6月19日付 執行役人事異動>
新任務:衛材(中国)投資有限公司 総経理(兼)衛材(中国)薬業有限公司 総経理(常務執行役)
旧任務:衛材(中国)投資有限公司 総経理(兼)衛材(中国)薬業有限公司 総経理(執行役)
氏名:ヤンホイ・フェン
新任務:エーザイデマンドチェーンシステムズ プレジデント(常務執行役)
旧任務:エーザイデマンドチェーンシステムズ プレジデント(執行役)
氏名:加藤 義輝
新任務:チーフガバメントリレーションズオフィサー(兼)グローバルバリュー&アクセス担当(常務執行役)
旧任務:チーフガバメントリレーションズオフィサー(兼)グローバルバリュー&アクセス担当 (執行役)
氏名:赤名 正臣
<2020年6月19日付 人事異動>
■グローバル本社
新任務:コーポレートベンチャーインベストメント部 ストラテジックインベストメントオフィサー(兼)日本・アジア室長(執行役員)
旧任務:コーポレートベンチャーインベストメント部 ストラテジックインベストメントオフィサー(兼)日本・アジア室長(理事職)
氏名:有賀 学
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2020/news202029.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
TANAKA to Provide Medals for the Tokyo Marathon 2026 That Represent All the Participants in the Event with Woven Lines
Feb 24, 2026 22:00 JST
Mitsubishi Shipbuilding Ships First Units of Systems for Marine Ammonia-Fueled Engines
Feb 24, 2026 20:07 JST
MHI Unveils "DIAVAULT," a Secure, High Performance Edge Data Center Platform
Feb 24, 2026 19:55 JST
Fujitsu expands Uvance for Finance offerings to accelerate DX across financial sector
Feb 24, 2026 11:23 JST
MHI Thermal Systems Establishes Local Subsidiary in India and Starts Operations
Feb 24, 2026 11:02 JST
Full Convertible Bond Conversion Removes Overhang and Signals Valuation Reassessment for Shoucheng Holdings
Feb 20, 2026 20:32 JST
Investee Companies Take the National Stage: Shoucheng Holdings' 'Capital+Scenario+Industry Chain' Strategy Validated, Entering the Value Realization Phase
Feb 20, 2026 20:06 JST
Hitachi Rail Invests C$30 Million in New Canadian Headquarters
Feb 20, 2026 12:20 JST
Toyota Launches New RAV4 (PHEV) in Japan
Feb 19, 2026 19:25 JST
Osaka Hospital launches project to safely utilize generative AI for healthcare workforce improvements
Feb 19, 2026 12:12 JST
MHI Machinery Systems Participates in Ramp Merging Support Demonstration Experiment for Autonomous Vehicles on the Tokyo Metropolitan Expressway
Feb 18, 2026 15:37 JST
IDC MarketScape names Hitachi Energy a Leader in Asset Performance Management for Worldwide Utilities
Feb 18, 2026 10:51 JST
Fujitsu named to FORTUNE Magazine's list of 'World's Most Admired Companie's for eighth year running
Feb 18, 2026 10:41 JST
Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR Dietary Supplement
Feb 17, 2026 22:00 JST
Fujitsu automates entire software development lifecycle with new AI-Driven Software Development Platform
Feb 17, 2026 12:21 JST
Snow master Evans leads 1-2-3-4 finish for TGR-WRT
Feb 16, 2026 15:24 JST
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
Feb 16, 2026 14:03 JST
Fujitsu and 1Finity to highlight latest network technologies and AI solutions at MWC Barcelona 2026
Feb 13, 2026 22:50 JST
Fujitsu to present latest technologies for creating social and industrial value through fusion of AI and computing at India AI Impact Summit 2026
Feb 13, 2026 22:33 JST
Mitsubishi Power Hosts Inaugural Energy Forward Forum in Indonesia with Government and Industry Experts
Feb 13, 2026 22:24 JST
More Latest Release >>
Related Release
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
2/16/2026 2:03:00 PM JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
2/10/2026 1:34:00 PM JST
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
2/6/2026 11:31:00 AM JST
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
1/26/2026 11:37:00 AM JST
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
1/21/2026 4:44:00 PM JST
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
1/13/2026 9:50:00 AM JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
1/6/2026 10:43:00 AM JST
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
12/11/2025 7:41:00 PM JST
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
12/9/2025 6:51:00 PM JST
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
12/4/2025 6:36:00 PM JST
More Press release >>